We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Vaccine Cures and Protects against West Nile Virus

By LabMedica International staff writers
Posted on 18 Apr 2018
Treatment with a novel siRNA-based vaccine offered efficient late-stage therapy and facilitated development of natural long-term immunity against West Nile virus in a mouse model system.

Short interfering RNAs (siRNAs) have a well-defined structure: a short (usually 21 base pairs) double-stranded RNA (dsRNA) with phosphorylated 5' ends and hydroxylated 3' ends with two overhanging nucleotides. More...
These small RNAs can bind to other specific messenger RNA (mRNA) molecules and either increase or decrease their activity, for example by preventing an mRNA from producing a protein. RNA interference has an important role in defending cells against parasitic nucleotide sequences – viruses and transposons – but also in directing development as well as gene expression in general.

No vaccines or therapeutics have been approved for West Nile virus (WNV), a mosquito-transmitted neuroencephalitic flavivirus. The small interfering RNA siFvEJW targets a conserved sequence within the WNV E protein and limits virus infection.

Investigators at Yale University (New Haven, CT, USA) reported in the March 29, 2018, online edition of the journal Cell Host & Microbe that they had used a rabies virus-derived neuron-targeting peptide (RVG9R) and an intranasal route to deliver siFvEJW to the central nervous system (CNS). Results demonstrated full recovery by WNV-infected mice at late stages of the neuroinvasive disease.

Selectively targeting viruses in the CNS lowered viral burdens in the brain, reduced neuropathology, and resulted in a 90% survival rate at five to six days post-infection (when viral titers peak in the CNS), while placebo-treated mice succumbed by days nine to 10. Importantly, CNS virus clearance was achieved by humoral and cell-mediated immune responses to WNV infection in peripheral tissues, which also brought about sterilizing immunity against subsequent WNV infection.

"Compared to mice that were given a placebo, the mice that were administered the therapy had a 90% survival rate a few days after infection. In fact, in the mice that survived, the immune system was able to rid of the virus throughout the body and provide long-term protection. It prevents pathology in the brain and gives the mice a chance to develop a robust immune response," said senior author Dr. Priti Kumar, associate professor of infectious diseases at Yale University. "In translation, it should be an effective strategy for people."

Related Links:
Yale University


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Sample Transportation System
Tempus1800 Necto
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.